Transfer learning is a standard technique to transfer knowledge from one domain to another. For applications in medical imaging, transfer from ImageNet has become the de-facto approach, despite differences in the tasks and image characteristics between the domains. However, it is unclear what factors determine whether - and to what extent transfer learning to the medical domain is useful. The longstanding assumption that features from the source domain get reused has recently been called into question. Through a series of experiments on several medical image benchmark datasets, we explore the relationship between transfer learning, data size, the capacity and inductive bias of the model, as well as the distance between the source and target domain. Our findings suggest that transfer learning is beneficial in most cases, and we characterize the important role feature reuse plays in its success.

Identifying active compounds for a target is a time- and resource-intensive task in early drug discovery. Accurate bioactivity prediction using morphological profiles could streamline the process, enabling smaller, more focused compound screens. We investigate the potential of deep learning on unrefined single-concentration activity readouts and Cell Painting data, to predict compound activity across 140 diverse assays. We observe an average ROC-AUC of 0.744 ± 0.108 with 62% of assays achieving ≥0.7, 30% ≥0.8, and 7% ≥0.9. In many cases, the high prediction performance can be achieved using only brightfield images instead of multichannel fluorescence images. A comprehensive analysis shows that Cell Painting-based bioactivity prediction is robust across assay types, technologies, and target classes, with cell-based assays and kinase targets being particularly well-suited for prediction. Experimental validation confirms the enrichment of active compounds. Our findings indicate that models trained on Cell Painting data, combined with a small set of single-concentration data points, can reliably predict the activity of a compound library across diverse targets and assays while maintaining high hit rates and scaffold diversity. This approach has the potential to reduce the size of screening campaigns, saving time and resources, and enabling primary screening with more complex assays.

High content imaging assays can capture rich phenotypic response data for large sets of compound treatments, aiding in the characterization and discovery of novel drugs. However, extracting representative features from high content images that can capture subtle nuances in phenotypes remains challenging. The lack of high-quality labels makes it difficult to achieve satisfactory results with supervised deep learning. Self-Supervised learning methods have shown great success on natural images, and offer an attractive alternative also to microscopy images. However, we find that self-supervised learning techniques underperform on high content imaging assays. One challenge is the undesirable domain shifts present in the data known as batch effects, which are caused by biological noise or uncontrolled experimental conditions. To this end, we introduce Cross-Domain Consistency Learning (CDCL), a self-supervised approach that is able to learn in the presence of batch effects. CDCL enforces the learning of biological similarities while disregarding undesirable batch-specific signals, leading to more useful and versatile representations. These features are organised according to their morphological changes and are more useful for downstream tasks – such as distinguishing treatments and mechanism of action.

High Content Imaging (HCI) plays a vital role in modern drug discovery and development pipelines, facilitating various stages from hit identification to candidate drug characterization. Applying machine learning models to these datasets can prove challenging as they typically consist of multiple batches, affected by experimental variation, especially if different imaging equipment have been used. Moreover, as new data arrive, it is preferable that they are analyzed in an online fashion. To overcome this, we propose CODA, an online self-supervised domain adaptation approach. CODA divides the classifier’s role into a generic feature extractor and a task-specific model. We adapt the feature extractor’s weights to the new domain using cross-batch self-supervision while keeping the task-specific model unchanged. Our results demonstrate that this strategy significantly reduces the generalization gap, achieving up to a 300% improvement when applied to data from different labs utilizing different microscopes. CODA can be applied to new, unlabeled out-of-domain data sources of different sizes, from a single plate to multiple experimental batches.